Abstract: The ocean is rich in structurally novel compounds of antitumor activity. The development of marine antitumor active substances and patents is important for the industrialization of marine antitumor drugs. The article expounds several marine antitumor active substances that have been marketed or are entering the clinical stage. It analyzes the novel compound sources bottlenecks, talent bottlenecks and policies bottlenecks in the R&D innovation process, as well as the clinical bottlenecks, market bottlenecks and financial bottlenecks in the industrialization process of marine antitumor drugs in China. The effort highlights the viewpoint that the application rate of marine antitumor products can be increased greatly by the construction of antitumor germplasm resource library or gene library to accurately design the drugs, and by the construction of national marine drugs industrialized innovation platforms and drugs outsourcing research institutions to inhance “Industry-University-Institute” cooperation, and by expanding diversifying antitumor products to form unique directions and industrialized development of marine antitumor drugs in China.